Shares of Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) have lost almost 60 percent of their value in the last month, after the phase 2 STAR 1 clinical … Read More

The post cannabinoid therapies appeared first on Dagga Magazine.

…read more